Arcus Biosciences Stock Market Value
| RCUS Stock | USD 18.92 1.04 5.21% |
| Symbol | Arcus |
Is there potential for Biotechnology market expansion? Will Arcus introduce new products? Factors like these will boost the valuation of Arcus Biosciences. Anticipated expansion of Arcus directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.42) | Revenue Per Share | Quarterly Revenue Growth (0.46) | Return On Assets | Return On Equity |
Arcus Biosciences's market price often diverges from its book value, the accounting figure shown on Arcus's balance sheet. Smart investors calculate Arcus Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Arcus Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Arcus Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Arcus Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Arcus Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arcus Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arcus Biosciences.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Arcus Biosciences on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Arcus Biosciences or generate 0.0% return on investment in Arcus Biosciences over 90 days. Arcus Biosciences is related to or competes with Immunitybio, Denali Therapeutics, Galapagos, Cogent Biosciences, Agios Pharm, Viridian Therapeutics, and Beam Therapeutics. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the... More
Arcus Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arcus Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arcus Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.99 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 19.63 | |||
| Value At Risk | (6.55) | |||
| Potential Upside | 5.64 |
Arcus Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcus Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arcus Biosciences' standard deviation. In reality, there are many statistical measures that can use Arcus Biosciences historical prices to predict the future Arcus Biosciences' volatility.| Risk Adjusted Performance | 0.0162 | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.27) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0541 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcus Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcus Biosciences February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0162 | |||
| Market Risk Adjusted Performance | 0.0641 | |||
| Mean Deviation | 2.91 | |||
| Semi Deviation | 4.81 | |||
| Downside Deviation | 4.99 | |||
| Coefficient Of Variation | 9890.07 | |||
| Standard Deviation | 4.07 | |||
| Variance | 16.55 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0) | |||
| Total Risk Alpha | (0.27) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0541 | |||
| Maximum Drawdown | 19.63 | |||
| Value At Risk | (6.55) | |||
| Potential Upside | 5.64 | |||
| Downside Variance | 24.92 | |||
| Semi Variance | 23.1 | |||
| Expected Short fall | (2.63) | |||
| Skewness | (0.93) | |||
| Kurtosis | 2.04 |
Arcus Biosciences Backtested Returns
Arcus Biosciences secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of standard deviation over the last 3 months. Arcus Biosciences exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arcus Biosciences' mean deviation of 2.91, and Risk Adjusted Performance of 0.0162 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arcus Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arcus Biosciences is expected to be smaller as well. At this point, Arcus Biosciences has a negative expected return of -0.0175%. Please make sure to confirm Arcus Biosciences' downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Arcus Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.24 |
Weak predictability
Arcus Biosciences has weak predictability. Overlapping area represents the amount of predictability between Arcus Biosciences time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arcus Biosciences price movement. The serial correlation of 0.24 indicates that over 24.0% of current Arcus Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.24 | |
| Spearman Rank Test | -0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 1.44 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.